source
- Crystalys nets $130M more to push gout drug through late-stage testsThe startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in t…BioPharma Dive · 6d ago↗ source
- Summit reports two-year survival data for Western patients, though context lackingSummit Therapeutics unveiled additional follow-up data on its experimental cancer drug ivonescimab, and how its benefit compares between Asian and Western patients. But key context remains unknown.…Endpoints · 6d ago↗ source
- Celldex scraps antibody in prurigo nodularis after Phase 2 flopCelldex said on Tuesday it will stop investigating its mast cell-targeting monoclonal antibody in a type of chronic itch disease after it failed on all efficacy measures in a mid-stage trial. Topli…